Titolo	Data di pubblicazione	Autore(i)
1	Wound botulism after traumatic open fracture in Italy	2015	De Rosa, Francesco Giuseppe; Stella, Maria Laura; Astegiano, Sara; Corcione, Silvia; Motta, Ilaria; Decastelli, Lucia; Di Perri, Giovanni
2	Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?	2004	DI PERRI G; BONORA S
3	When and how to use maraviroc in HIV-infected patients	2009	Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM.
4	What do we know about tailoring treatment with tenofovir?	2016	Calcagno, Andrea; Di Perri, Giovanni; Bonora, Stefano
5	West African Immigrants and New Patterns of Malaria Imported to North Eastern Italy.	1994	DI PERRI G ;SOLBIATI M ;VENTO S ;DE CHECCHI G ;LUZZATI R ;BONORA S ;MERIGHI M ;MAROCCO S ;FIBBIA G ;CONCIA E
6	Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.	2014	Calcagno A;Baietto L;Pagani N;Simiele M;Audagnotto S;D'Avolio A;De Rosa FG;Di Perri G;Bonora S
7	Vitamin D pathway polymorphisms impact on HBV interferon treatment outcomes in a cohort of HBeAg negative patients	2015	Cusato, Jessica; Boglione, Lucio; De Nicolo’, Amedeo; Cardellino, Chiara Simona; Imbornone, Rosaria; Cariti, Giuseppe; Di Perri, Giovanni; D’Avolio, Antonio
8	Vitamin D pathway genetic variants are able to influence sofosbuvir and its main metabolite pharmacokinetics in HCV mono-infected patients	2018	Cusato, Jessica; De Nicolò, Amedeo; Boglione, Lucio; Favata, Fabio; Ariaudo, Alessandra; Mornese Pinna, Simone; Carcieri, Chiara; Guido, Federica; Avataneo, Valeria; Cariti, Giuseppe; Di Perri, Giovanni; D'Avolio, Antonio
9	Vitamin D pathway gene variants and HCV-2/3 therapy outcomes.	2015	Cusato, Jessica; Allegra, Sarah; Boglione, Lucio; DE NICOLO', Amedeo; Baietto, Lorena; Cariti, G; DI PERRI, Giovanni; D'Avolio, Antonio
10	Vitamin D pathway gene polymorphisms as predictors of hepatitis C virus-related mixed cryoglobulinemia	2016	Cusato, Jessica; Boglione, Lucio; DE NICOLO', Amedeo; Cardellino, Chiara Simona; Carcieri, Chiara; Cariti, Giuseppe; DI PERRI, Giovanni; D'Avolio, Antonio
11	Vitamin D pathway gene polymorphisms and hepatocellular carcinoma in chronic hepatitis C-affected patients treated with new drugs	2018	Cusato, Jessica; Boglione, Lucio; De Nicolò, Amedeo; Favata, Fabio; Ariaudo, Alessandra; Mornese Pinna, Simone; Guido, Federica; Avataneo, Valeria; Cantù, Marco; Carcieri, Chiara; Cariti, Giuseppe; Di Perri, Giovanni; D'Avolio, Antonio
12	Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy	2018	Cusato, Jessica; Nicolò, Amedeo De; Boglione, Lucio; Favata, Fabio; Ariaudo, Alessandra; Pinna, Simone Mornese; Carcieri, Chiara; Guido, Federica; Cariti, Giuseppe; Perri, Giovanni Di; D'Avolio, Antonio
13	Virological response and safety in a cohort of immigrant patients affected by chronic hepatitis delta treated with PEG-IFN	2018	Boglione, L.; Cariti, G.; Lupia, T.; Pinna, S.M.; Ghisetti, V.; DI Perri, G.
14	Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study	2008	Santoro MM, Bertoli A, Lorenzini P, Lazzarin A, Esposito R, Carosi G, Di Perri G, Filice G, Moroni M, Rizzardini G, Caramello P, Maserati R, Narciso P, Cargnel A, Antinori A, Perno CF; CARe Study Group
15	Very high pre-therapy viral load is a predictor of virological rebound in HIV-1-infected patients starting a modern first-line regimen	2019	Armenia, Daniele; Di Carlo, Domenico; Cozzi-Lepri, Alessandro; Calcagno, Andrea; Borghi, Vanni; Gori, Caterina; Bertoli, Ada; Gennari, William; Bellagamba, Rita; Castagna, Antonella; Latini, Alessandra; Pinnetti, Carmela; Cicalini, Stefania; Saracino, Annalisa; Lapadula, Giuseppe; Rusconi, Stefano; Castelli, Francesco; Di Giambenedetto, Simona; Andreoni, Massimo; Di Perri, Giovanni; Antinori, Andrea; Mussini, Cristina; Ceccherini-Silberstein, Francesca; Monforte, Antonella D'Arminio; Perno, Carlo F; Santoro, Maria M
16	VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia.	2015	Cusato, Jessica; Allegra, Sarah; Boglione, Lucio; DE NICOLO', Amedeo; Cariti, G; DI PERRI, Giovanni; D'Avolio, Antonio
17	VDR gene polymorphisms impact on anemia at 2 week of anti-HCV therapy: a possible mechanism for early RBV-induced anemia.	2015	Cusato, Jessica; Allegra, Sarah; Boglione, Lucio; De Nicolò, Amedeo; Cariti, Giuseppe; Di Perri, Giovanni; D’Avolio, Antonio
18	Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients	2006	D'AVOLIO A; IBAÑEZ A; SCIANDRA M; SICCARDI M; DE REQUENA DG; BONORA S; DI PERRI G
19	UTILITA' DEL THERAPEUTIC DRUG MONITORING DI NEVIRAPINA	2002	Boffito M.; Bonora S.; Sciandra M.; D'Avolio A.; Gramoni A.; Sales P.; Trentini L.; Sciolè K.; Caci A.M.; Sinicco A.; Raiteri R.; Di Perri G.
20	Usefulness of therapeutic drug monitoring of posaconazole in haematological adult patients	2011	L. Baietto; F.G. De Rosa; A. D’Avolio; E. Biasin; F. Nesi; F. Saglio; C. Marra; S. Pace; G. Di Perri